

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that VorFat System (the “**Device**”), which adopts a new technique of micronized fraction of the adipose tissue independently developed by the Company, received the clearance from the U.S. Food and Drug Administration (“**FDA**”) on June 12, 2023 for marketing in the United States. The Device was granted a patent in the United States on November 29, 2022 (Patent No.: US 11511031).

The Device is intended for the closed-loop processing of microfragment adipose tissue for re-injection in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue harvested with a lipoplasty system. It is also intended for use in the following surgical specialties while the transfer of harvested adipose tissue for aesthetic body contouring is desired: orthopedic surgery; arthroscopic surgery; neurosurgery; gastrointestinal and affiliated organ surgery; urological surgery; general surgery; gynecological surgery; thoracic surgery; laparoscopic surgery; and plastic and reconstructive surgery. As at the date of this announcement, the Company has received wide indications for the Device.

The Company believes that FDA’s clearance of the Device will further strengthen the Company’s product portfolio and product competitiveness and will also solidifies the Company’s position as one of the technology and market leaders in the global aesthetic market.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, June 16, 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as executive directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*